Answers are grounded in this paper and cite their sources.
India’s dermatopathology community is enriched by a wide range of academic initiatives conducted by the Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) and the Dermatopathology Society of India (DSI). These include regular workshops, Continuing Medical Education (CME) programs, Dermatopathology Quiz of the Month, and DSI’s postgraduate quiz competitions. Interactive case discussions and microscopy sessions further contribute to learning, particularly through journals such as the Indian Journal of Dermatology, Venereology and Leprology (IJDVL) and the Indian Journal of Dermatopathology and Diagnostic Dermatology (IJDPDD). In this context, Dr. Arti Bakshi’s introduction to External Quality Assessment (EQA) at the recent DSI meeting in Visakhapatnam,[1] informed by her experience with the UK’s National Specialist Dermatopathology EQA (NSDEQA),[2] underscored the transformative potential of such a system. Yet, these existing efforts—though invaluable—lack the objective, systematic evaluation of competence offered by a formal EQA scheme. In a country without a recognized dermatopathology degree, an EQA program is critical to uphold diagnostic quality, promote learning, and strengthen professional development. This editorial proposes a framework tailored for India, outlining structure, assessment methods, and the rationale for collective action. The Indian Context: Addressing Variability Dermatopathology training in India is highly variable—ranging from brief residency rotations and informal observerships to short fellowships or self-directed study. This heterogeneity contributes to inconsistent diagnostic accuracy across practitioners. Many reporting pathologists lack formal dermatology training and may struggle to synthesize histopathological findings with clinical context. Reports often default to confirming or refuting the referring clinician’s differentials rather than offering independent, tiered interpretations. While educational initiatives foster engagement, they do not provide the systematic, objective benchmarking of diagnostic competence that a formal examination or External Quality Assessment (EQA) scheme would enable. An EQA scheme, inspired by the UK National External Quality Assessment Service (UK NEQAS) and its interpretive dermatopathology arm (NSDEQA), would standardize skills, complementing our educational ecosystem and addressing India’s challenges.[2,3] It would also address India’s unique challenges: diverse disease profiles, geographical disparities, and the absence of formal certification in dermatopathology. Structuring an EQA Scheme An effective Indian dermatopathology EQA scheme should be digital, voluntary, educational, and inclusive. Core components would include: Case circulation Three cycles annually. Each cycle includes 10–20 digitized cases (e.g., high-resolution JPEGs, up to 30 MB), covering inflammatory, infectious/tropical dermatoses, and skin tumours including lymphomas. Cases accessed via a secure, zoomable online viewer with annotation tools. Participant enrolment Open to dermatologists and pathologists—consultants and trainees. Annual registration (₹5000–10,000) to cover slide digitization (₹200/slide) and platform setup (approx. ₹50,000). Reduced fees or sponsorships for trainees via partnerships with labs or pharmaceutical companies will be expanded to maximize participation, fostering a pipeline of skilled dermatopathologists. Minimum participation: 2 out of 3 annual cycles. Diagnostic submission Participants assign one diagnosis (100% weight) or multiple differentials summing to 100% (e.g., 70/30 or 50/30/15/5). Selection from a dropdown of 4000–5000 terms with autocomplete (e.g., typing “Melan” suggests “Melanoma”). Submissions remain anonymized using participant IDs (e.g., “Participant 001”), with encrypted storage and GDPR-like privacy compliance. Timeframe: 4–6 weeks per cycle. Consensus and feedback Post-cycle virtual panel discussions establish consensus diagnoses. To minimize subjectivity, particularly for complex cases such as cutaneous lymphomas, these discussions will follow standardized guidelines, including predefined diagnostic criteria and structured deliberation protocols. Feedback includes: submitted answers, consensus, score, and percentile—sent via anonymized PDF within 6 weeks. CPD credits Consultants may earn 2 CPD credits per cycle and 1 for virtual discussion attendance (up to 9 annually). Accreditation may be sought from the National Medical Commission, State Medical Councils, National Board of Examinations, or IADVL. CPD criteria reviewed every 5 years to maintain regulatory alignment. Marking and Assessment Assessment is educational, encouraging nuanced diagnostic reasoning: Scoring System ○ The expert panel evaluates each case’s consensus diagnosis: correct (1 point), partially correct (0.5 points), or incorrect (0 points). ○ Participant scores are calculated by multiplying the panel’s points by the participant’s assigned weight for each diagnosis (weights total 100 points). ○ Example: A participant submits two diagnoses—Diagnosis A (70 points) and Diagnosis B (30 points). If Diagnosis A is partially correct (0.5) and Diagnosis B is correct (1.0), the score is (70 × 0.5) + (30 × 1.0) = 35 + 30 = 65 points. ○ For a single diagnosis (100 points), a correct submission yields 100 × 1.0 = 100 points; an incorrect one yields 100 × 0 = 0 points. Performance Feedback ○ Participants receive: ▪ Case-by-Case Results: Submitted diagnoses, weights, consensus diagnoses, and score (0–100). ▪ Cycle Total: Sum of case scores. ▪ Percentile Rank: Position relative to peers (e.g., “85th percentile”), calculated as (Rank - 1) / (N - 1) * 100, where N is total participants. ▪ Annual Average: Mean score and percentile across three cycles. ○ Feedback is anonymized, delivered via PDF, fostering learning without judgment. Performance Monitoring ○ No initial passing score; the focus is educational. ○ Participants in the bottom 3% in 2 of 3 cycles are flagged confidentially for reflection (e.g., via mentorship or appraisal), not sanctions. ○ Post-pilot, a performance threshold (e.g., 70%) may be set for consultants, with data-driven criteria for potential certification (e.g., top 75% over multiple cycles) developed after 3–5 years of evaluation. Trainee Assessment ○ Trainees receive identical feedback for self-assessment but are ineligible for certification or CPD credits, ensuring inclusivity while distinguishing roles. Benefits of an EQA Scheme Patient outcomes Reduces diagnostic errors and ensures timely treatment, especially in high-stakes conditions like cutaneous lymphomas. Quality assurance Objective benchmarking enhances reliability across diverse training backgrounds. Continuous learning Diverse, complex cases and percentile ranks encourage growth and reflection. Professional development CPD credits offer formal recognition, unlike quiz-based accolades. Inclusivity A digital model ensures participation from remote and under-resourced areas. Recognition pathway Consistent performance could serve as a credential in the absence of a formal dermatopathology degree. Moving Forward Dr. Arti Bakshi’s Visakhapatnam session, informed by her NSDEQA experience, demonstrated EQA’s feasibility, leveraging digital tools to manage costs (e.g., slide digitization, platform maintenance). A collaborative committee, potentially involving dermatology and pathology experts, could govern the scheme, ensuring transparency and inclusivity. Financial sustainability could be achieved through participant fees, with potential sponsorships from diagnostic laboratories or industry partners, and subsidies for trainees to maintain accessibility. Challenges like digital literacy can be addressed through user-friendly design and documentation. A pilot phase in 2025, targeting 20–30 participants, could test the scheme, refine standard operating procedures, and seek accreditation for CPD credibility. A Call to Action Our existing ecosystem—quizzes, microscopy sessions, and CMEs—demonstrates our community’s commitment to learning. However, only a structured EQA scheme can offer systematic, equitable assessment of competence. I urge dermatologists, pathologists, and academic leaders to support a 2025 pilot. Together, we can build a rigorous, inclusive framework that positions Indian dermatopathology as a global benchmark. Acknowledgement I thank Dr. Arti Bakshi for her inputs and advice regarding Indianising the UK NSDEQA scheme. Author contributions Dr. Sasi Kiran Attili is the sole author and was responsible for preparing, and approving the manuscript. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Sasi Kiran Attili (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: